New insider Kawas Leen claimed ownership of 4,367,100 shares (SEC Form 3)
$EIGR
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 10/18/2023 |
3. Issuer Name and Ticker or Trading Symbol
Eiger BioPharmaceuticals, Inc. [ EIGR ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 1,667,100 | I | See footnote(1)(3) |
| Common Stock | 2,700,000 | I | See footnote(2)(3) |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Explanation of Responses: |
| 1. Ms. Kawas controls Propel Bio Management LLC, a Delaware limited liability company ("Propel Management"). Ms. Kawas also shares control of Propel Bio Partners LLC, a Delaware limited liability company ("Propel General Partner"). Ms. Kawas, Propel Management and Propel General Partner act as the investment advisor to, or general partner of, or otherwise provide discretionary advisory services to, one or more private investment funds, and such investment funds directly own 1,667,100 shares of Common Stock. |
| 2. Propel Management acts as the investment advisor to an investment company registered under the Investment Company Act of 1940, as amended, and such investment company directly owns 2,700,000 shares of Common Stock. |
| 3. Ms. Kawas expressly disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of any pecuniary interest. |
| /s/ Leen Kawas | 10/30/2023 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||